title: [Assessment of renal abnormalities in 107 HIV patients treated with tenofovir].
abstract: OBJECTIVE
  The objectives of our study were to assess frequency, severity and outcome of renal abnormalities, as well as to determine the risk of developing hypophosphataemia in HIV-infected patients receiving tenofovir.
  
  
  METHODS
  An observational study was conducted in real-life conditions, during a 6-month period, in 107 HIV patients receiving tenofovir.
  
  
  RESULTS
  Mild-to-moderate hypophosphataemia (<0.77 mmol/L) occurred during follow-up, at least once in 43% of patients and at least twice in 27%. Antiretroviral therapy including ritonavir + lopinavir was significantly associated with the occurrence of hypophosphataemia (relative risk = 2.6; p = 0.03). Frequency of abnormal proteinuria was 22%.
  
  
  CONCLUSIONS
  Creatinine clearance, phosphataemia, proteinuria and glycosuria should be closely monitored in patients receiving tenofovir therapy.
authors.affiliation: Service des Maladies Infectieuses et Tropicales, Hôpital Gui de Chauliac, CHU Montpellier, Montpellier, France.
authors.forename: Pierre
authors.initials: P
authors.lastname: Lochet
authors.forename: Helène
authors.initials: H
authors.lastname: Peyrière
authors.forename: Vincent
authors.initials: V
authors.lastname: Le Moing
authors.forename: Jean-Pierre
authors.initials: JP
authors.lastname: Blayac
authors.forename: Sylvie
authors.initials: S
authors.lastname: Hansel
authors.forename: Jacques
authors.initials: J
authors.lastname: Reynes
mesh_terms: D000225:Adenine / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000328:Adult; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D007674:Kidney Diseases / Q000209:etiology* / Q000503:physiopathology; D007677:Kidney Function Tests; D008297:Male; D063065:Organophosphonates / Q000009:adverse effects* / Q000627:therapeutic use; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D000068698:Tenofovir
chemical_list: D063065:Organophosphonates; D018894:Reverse Transcriptase Inhibitors; D000068698:Tenofovir; D000225:Adenine